Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Xenobiotica ; 38(11): 1437-51, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18841517

ABSTRACT

1-[(2R)-2-([[(1S,2S)-1-amino-1,2,3,4-tetrahydronaphthalen-2-yl]carbonyl]amino)-3-(4-chlorophenyl)propanoyl]-N-(tert-butyl)-4-cyclohexylpiperidine-4-carboxamide (1) is a potent melanocortin-4 receptor agonist that exhibited time-dependent inhibition of cytochrome P450 (P450) 3A in incubations with human liver microsomes. In incubations fortified with potassium cyanide, a cyano adduct was identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis as a cyanonitrosotetrahydronaphthalenyl derivative. The detection of this adduct suggested that a nitroso species was involved in the formation of a metabolite intermediate (MI) complex that led to the observed P450 inactivation. Further evidence supporting this hypothesis derived from incubations of 1 with recombinant P450 3A4, which exhibited a lambda(max) at approximately 450 nm. The species responsible for this absorbance required the presence of beta-nicotinamide adenine dinucleotide phosphate reduced form (NADPH), increased with increasing incubation time and decreased following the addition of potassium ferricyanide to the incubation mixture, suggestive of an MI complex. Similar results were obtained with rat liver microsomes and with recombinant P450 3A1. When rats were dosed with indinavir as a P450 3A probe substrate, plasma exposure to indinavir increased three-fold following pretreatment with 1, consistent with drug-drug interaction projections based on the k(inact) and K(I) parameters for 1 in rat liver microsomes. A similar approach was used to predict the magnitude of the corresponding drug-drug interaction potential in humans dosed with a drug metabolized predominantly by P450 3A, and the forecast area under the curve (AUC) increase ranged from four- to ten-fold. These data prompted a decision to terminate further evaluation of 1 as a development candidate, and led to the synthesis of the methyl analogue 2. Methyl substitution alpha to the amino group in 2 was designed to reduce the propensity for formation of a nitroso intermediate and, indeed, 2 failed to exhibit time-dependent inhibition of P450 3A in human liver microsomal incubations. This case study highlights the importance of mechanistic studies in support of drug-discovery and decision-making processes.


Subject(s)
1-Naphthylamine/analogs & derivatives , Cytochrome P-450 CYP3A Inhibitors , Enzyme Inhibitors/chemistry , Piperidines/chemistry , Receptor, Melanocortin, Type 4/agonists , 1-Naphthylamine/chemistry , 1-Naphthylamine/metabolism , 1-Naphthylamine/pharmacology , Animals , Binding Sites , Cytochrome P-450 CYP3A/metabolism , Drug Discovery , Drug Interactions , Enzyme Inhibitors/metabolism , Male , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Piperidines/metabolism , Piperidines/pharmacology , Rats , Rats, Sprague-Dawley , Receptor, Melanocortin, Type 4/metabolism , Tandem Mass Spectrometry
2.
Endocrinology ; 145(6): 2607-12, 2004 Jun.
Article in English | MEDLINE | ID: mdl-14962995

ABSTRACT

Ghrelin, a stomach-derived orexigenic hormone, has stimulated great interest as a potential target for obesity control. Pharmacological evidence indicates that ghrelin's effects on food intake are mediated by neuropeptide Y (NPY) and agouti-related protein (AgRP) in the central nervous system. These include intracerebroventricular application of antibodies to neutralize NPY and AgRP, and the application of an NPY Y1 receptor antagonist, which blocks some of the orexigenic effects of ghrelin. Here we describe treatment of Agrp(-/-);Npy(-/-) and Mc3r(-/-);Mc4r(-/-) double knockout mice as well as Npy(-/-) and Agrp(-/-) single knockout mice with either ghrelin or an orally active nonpeptide ghrelin agonist. The data demonstrate that NPY and AgRP are required for the orexigenic effects of ghrelin, as well as the involvement of the melanocortin pathway in ghrelin signaling. Our results outline a functional interaction between the NPY and AgRP pathways. Although deletion of either NPY or AgRP caused only a modest or nondetectable effect, ablation of both ligands completely abolished the orexigenic action of ghrelin. Our results establish an in vivo orexigenic function for NPY and AgRP, mediating the effect of ghrelin.


Subject(s)
Appetite/physiology , Neuropeptide Y/physiology , Peptide Hormones/physiology , Proteins/physiology , Agouti-Related Protein , Animals , Appetite/drug effects , Ghrelin , Intercellular Signaling Peptides and Proteins , Mice , Mice, Inbred C57BL , Mice, Knockout , Peptide Hormones/pharmacology , Receptor, Melanocortin, Type 3/physiology , Receptor, Melanocortin, Type 4/physiology , Receptors, G-Protein-Coupled/physiology , Receptors, Ghrelin
3.
Bioorg Med Chem Lett ; 11(14): 1955-7, 2001 Jul 23.
Article in English | MEDLINE | ID: mdl-11459669

ABSTRACT

A series of small molecules derived from MK-0677, a potent synthetic GHS, mimicking the N-terminal Gly-Ser-O-(n-octanoyl)-L-Ser-Phe segment of ghrelin was synthesized and tested in a binding and in a functional assay measuring intracellular calcium elevation in HEK-293 cells expressing hGHSR1a. Replacement of Phe in this tetrapeptide with a spiro(indoline-3,4'-piperidine) group, Gly-Ser with 2-aminoisobutyric acid, and O-(n-octanoyl)-L-Ser with O-benzyl-D-Ser provided synthetic GHS agonists with similar functional potency as ghrelin.


Subject(s)
Calcium/metabolism , Indoles/metabolism , Peptide Hormones , Peptides/metabolism , Piperidines/metabolism , Receptors, Cell Surface/metabolism , Receptors, G-Protein-Coupled , Spiro Compounds/metabolism , Binding Sites/physiology , Cells, Cultured , Ghrelin , Humans , Indoles/chemistry , Inhibitory Concentration 50 , Luminescence , Molecular Mimicry , Peptides/chemistry , Piperidines/chemical synthesis , Protein Binding/physiology , Receptors, Ghrelin , Spiro Compounds/chemistry
4.
Trends Pharmacol Sci ; 22(3): 132-40, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11239576

ABSTRACT

The superfamily of seven-transmembrane-domain G-protein-coupled receptors (GPCRs) is the largest and most diverse group of transmembrane proteins involved in signal transduction. Each of the approximately 1000 family members found in vertebrates responds to stimuli as diverse as hormones, neurotransmitters, odorants and light, which selectively activate intracellular signaling events mediated by heterotrimeric G proteins. Because GPCRs are centrally positioned in the plasma membrane to initiate a cascade of cellular responses by diverse extracellular mediators, it is not surprising that modulation of GPCR function has been successful in the development of many marketed therapeutic agents. It has become clear that GPCRs for which a natural activating ligand has not yet been identified (orphan GPCRs) might provide a path to discovering new cellular substances that are important in human physiology. The process of 'de-orphanizing' these novel proteins has accelerated significantly and opened up new avenues for research in human physiology and pharmacology.


Subject(s)
Receptors, Odorant/pharmacology , Receptors, Odorant/physiology , Animals , Humans , Ligands , Receptors, Odorant/isolation & purification , Signal Transduction
5.
Bioorg Med Chem Lett ; 10(1): 5-8, 2000 Jan 03.
Article in English | MEDLINE | ID: mdl-10636230

ABSTRACT

Quinazolinone derivatives were synthesized and evaluated as non-peptidic growth hormone secretagogues. Modeling guided design of quinazolinone compound 21 led to a potency enhancement of greater than 200-fold compared to human growth hormone secretagogue affinity of a screening lead 4.


Subject(s)
Drug Design , Human Growth Hormone/metabolism , Quinazolines/chemical synthesis , Quinazolines/pharmacology , Receptors, Cell Surface/agonists , Receptors, G-Protein-Coupled , Animals , Binding Sites , Humans , Inhibitory Concentration 50 , Kinetics , Models, Molecular , Quinazolines/chemistry , Quinazolines/metabolism , Rats , Receptors, Cell Surface/metabolism , Receptors, Ghrelin , Secretory Rate/drug effects , Structure-Activity Relationship
7.
Bioorg Med Chem Lett ; 8(7): 759-64, 1998 Apr 07.
Article in English | MEDLINE | ID: mdl-9871537

ABSTRACT

A series of C-terminus capped dipeptides and tripeptides was synthesized as growth hormone (GH) secretagogues. Among them, tripeptide Aib-D-Trp-D-homoPhe-OEt showed low nanomolar activity in the rat pituitary assay. Thus, we have demonstrated that the GH secretagogue activity of the hexa-hepta-GH releasing peptides can be mimicked at the tripeptide level.


Subject(s)
Dipeptides/chemical synthesis , Growth Hormone/metabolism , Oligopeptides/chemical synthesis , Amino Acid Sequence , Animals , Dipeptides/chemistry , Dipeptides/pharmacology , In Vitro Techniques , Models, Molecular , Molecular Structure , Oligopeptides/chemistry , Oligopeptides/pharmacology , Pituitary Gland/metabolism , Rats , Structure-Activity Relationship
8.
Bioorg Med Chem Lett ; 8(11): 1431-6, 1998 Jun 02.
Article in English | MEDLINE | ID: mdl-9871779

ABSTRACT

A new class of potent, orally active phenyl piperazine-based GH secretagogues have been discovered from attempts to mimic the arrangement of the phenyl substituent in the spiroindanyl piperidine and spiroindoline sulfonamide privileged structures of 4 and 1, respectively. The best of these compounds, 18 (EC50 = 2.8 nM) is nearly as potent as MK-0677 for releasing GH from rat pituitary cells.


Subject(s)
Growth Hormone/metabolism , Peptides/chemistry , Piperazines/chemical synthesis , Sulfonamides/chemical synthesis , Animals , Cells, Cultured , Drug Design , Indoles/pharmacology , Molecular Mimicry , Piperazines/pharmacology , Pituitary Gland/cytology , Pituitary Gland/drug effects , Pituitary Gland/metabolism , Rats , Spiro Compounds/pharmacology , Stimulation, Chemical , Structure-Activity Relationship , Sulfonamides/pharmacology
10.
J Endocrinol ; 152(2): 183-92, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9071975

ABSTRACT

We have reported that MK-0677 is a novel, orally active GH secretagogue that stimulates an immediate and long-lasting increase in serum GH levels in dogs. Significant elevations in IGF-I levels were associated with the increased GH secretion. Cortisol secretion was also increased following MK-0677 administration. In the current study, we determined the effect of repeat oral administration of MK-0677 on GH, IGF-I and cortisol levels; we also investigated if the GH and cortisol responses to MK-0677 are influenced by circulating IGF-I concentrations. Following the initial oral administration of MK-0677, GH secretion (area under the time-response curve (AUC) ng/ml per h) was increased 7.9- to 9.8-fold (1.0 mg/kg), 5.6-fold (0.5 mg/kg) or 3.9-fold (0.25 mg/kg). With repeat MK-0677 administration, the GH response was decreased by 41-77%; GH concentrations remained significantly above control in the 0.5 mg/kg and 1.0 mg/kg groups. Individual beagle GH profiles indicated that the increased GH concentration was associated with an amplified GH pulsatile profile. Serum IGF-I levels were significantly increased over control levels at all dosage levels by 480 min on the first day of MK-0677 administration. With repeated administration, IGF-I levels were increased up to 126% and remained elevated through 14 days, the longest treatment period evaluated. While daily MK-0677 administration appeared to increase IGF-I levels over 24 h, as evidenced by significant increases in the pretreatment IGF-I levels on days 4-14, no such increase was noted with alternate day MK-0677 administration; thus the dosage regimen modulated circulating IGF-I levels. MK-0677 stimulated increases in cortisol secretion (AUC microgram/dl per h) on the first day of treatment. A decreased cortisol response was observed following repeated daily treatment with MK-0677; in contrast, with alternate day treatment, no decrease in cortisol response to MK-0677 occurred. A marked increase in circulating IGF-I concentrations following administration of exogenous GH resulted in a significant decrease in both the GH and cortisol response to MK-0677 compared with control animals. Our findings suggested, therefore, that circulating IGF-I concentrations regulate GH and cortisol response to MK-0677. In summary, chronic oral administration of MK-0677 was associated with significant increases in GH and IGF-I levels that were maintained for the duration of the treatment. The GH profile following MK-0677 administration consisted of episodic increases above control. Compared with day 1, repeated daily treatment with MK-0677 resulted in an attenuated GH response that was associated with an increase in circulating IGF-I levels. The cortisol response was similarly reduced during chronic MK-0677 treatment, suggesting that IGF-I mediated negative feedback on both the GH and cortisol axes. The fact that similar attenuation of the GH and cortisol responses to MK-0677 on day 1 was observed if IGF-I levels were increased by treating animals with exogenous GH suggested that the attenuated response to MK-0677 that occurred during chronic treatment was mediated by increases in IGF-I rather than desensitization to MK-0677. Thus, a regulatory feedback loop apparently prevents hyperstimulation of the GH axis by MK-0677. We conclude that MK-0677 offers the potential of an orally active GH secretagogue that can maintain elevated IGF-I levels when administered chronically.


Subject(s)
Growth Hormone/metabolism , Indoles/pharmacology , Insulin-Like Growth Factor I/metabolism , Spiro Compounds/pharmacology , Animals , Dogs , Feedback , Female , Growth Hormone/blood , Growth Hormone/pharmacology , Hydrocortisone/blood , Hydrocortisone/metabolism , Insulin-Like Growth Factor I/analysis , Male , Stimulation, Chemical , Time Factors
12.
Mol Endocrinol ; 10(1): 57-61, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8838145

ABSTRACT

The potential application of small molecules in GH therapy has recently become a topic of increasing interest. The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human. Moreover, these synthetic GH secretagogues act on a signal transduction pathway distinct from that of GHRH. A specific high affinity binding site in porcine and rat anterior pituitary membranes that mediates the activity of these secretagogues has now been identified. The binding affinity of these structurally diverse secretagogues is tightly correlated with GH-secretory activity. The binding is Mg(2+)-dependent, is inhibited by GTP-gamma-S, and is not displaced by GHRH and somatostatin. The receptor is distinct from that for GHRH and has the properties of a new G-protein-coupled receptor. It is speculated that these GH secretagogues mimic an unidentified natural hormone that regulates GH secretion in concert with GHRH and somatostatin.


Subject(s)
GTP-Binding Proteins/physiology , Growth Hormone/metabolism , Indoles/metabolism , Receptors, Cell Surface/metabolism , Spiro Compounds/metabolism , Animals , Benzazepines/metabolism , Binding, Competitive , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Magnesium/pharmacology , Male , Oligopeptides/metabolism , Pituitary Gland, Anterior/metabolism , Rats , Rats, Wistar , Receptors, Somatotropin/metabolism , Swine , Tetrazoles/metabolism
13.
Proc Natl Acad Sci U S A ; 92(15): 7001-5, 1995 Jul 18.
Article in English | MEDLINE | ID: mdl-7624358

ABSTRACT

A potent, orally active growth hormone (GH) secretagogue L-163,191 belonging to a recently synthesized structural class has been characterized. L-163,191 releases GH from rat pituitary cells in culture with EC50 = 1.3 +/- 0.09 nM and is mechanistically indistinguishable from the GH-releasing peptide GHRP-6 and the prototypical nonpeptide GH secretagogue L-692,429 but clearly distinguishable from the natural GH secretagogue, GH-releasing hormone. L-163,191 elevates GH in dogs after oral doses as low as 0.125 mg/kg and was shown to be specific in its release of GH without significant effect on plasma levels of aldosterone, luteinizing hormone, thyroxine, and prolactin after oral administration of 1 mg/kg. Only modest increases in cortisol were observed. Based on these properties, L-163,191 has been selected for clinical studies.


Subject(s)
Growth Hormone/metabolism , Indoles/administration & dosage , Pituitary Gland/drug effects , Spiro Compounds/administration & dosage , Administration, Oral , Aldosterone/blood , Amino Acid Sequence , Animals , Benzazepines/pharmacology , Cells, Cultured , Dogs , Drug Design , Drug Synergism , Indoles/pharmacology , Injections, Intravenous , Luteinizing Hormone/blood , Male , Molecular Sequence Data , Oligopeptides , Prolactin/blood , Rats , Spiro Compounds/pharmacology , Structure-Activity Relationship , Tetrazoles/pharmacology , Thyroxine/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...